Research Article Anticancer, Anti-Inflammatory, and Analgesic Activities of Synthesized 2-(Substituted phenoxy) Acetamide Derivatives Priyanka Rani, 1 Dilipkumar Pal, 2 Rahul Rama Hegde, 3 and Syed Riaz Hashim 4 1 Department of Chemistry, School of Sciences, IFTM University, Moradabad, Uttar Pradesh, India 2 Department of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Koni, Bilaspur, Chhattisgarh 495 009, India 3 Department of Pharmaceutics, School of Pharmaceutical Sciences, IFTM University, Moradabad, Uttar Pradesh, India 4 Department of Chemistry, School of Pharmaceutical Sciences, IFTM University, Moradabad, Uttar Pradesh, India Correspondence should be addressed to Priyanka Rani; skifm@gmail.com Received 27 February 2014; Revised 22 July 2014; Accepted 29 July 2014; Published 14 August 2014 Academic Editor: Raymond L. Konger Copyright © 2014 Priyanka Rani et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Te aphorism was to develop new chemical entities as potential anticancer, anti-infammatory, and analgesic agents. Te Leuckart synthetic pathway was utilized in development of novel series of 2-(substituted phenoxy)-N-(1-phenylethyl)acetamide derivatives. Te compounds containing 1-phenylethylamine as basic moiety attached to substituted phenols were assessed for their anticancer activity against MCF-7 (breast cancer), SK-N-SH (neuroblastoma), anti-infammatory activity, and analgesic activity. Tese investigations revealed that synthesized products 3a–j with halogens on the aromatic ring favors as the anticancer and anti- infammatory activity. Among all, compound 3c N-(1-(4-chlorophenyl)ethyl)-2-(4-nitrophenoxy)acetamide exhibited anticancer, anti-infammatory, and analgesic activities. In conclusion, 3c may have potential to be developed into a therapeutic agent. 1. Introduction In the past decade, numerous advances have taken place in the understanding of pathogenesis of cancer and its relationship with infammation. To date the research work on this ground is substantial, but it still lacks clinical accomplish- ment, with the existing development facade over the clinical exploitation of drugs with dual acting cyclooxygenase-2 (COX-2) inhibition and antiproliferative potency [1]. When- ever cells in the body are allowed to divide uncontrollably and to metastasize, this results in the formation of cancer. Large scale of studies indicates that overexpression of COX- 2 strongly appeared in human breast carcinomas approx- imately 40% and in colorectal carcinomas approximately 60%. In particular, COX-2 is found during overexpression of human epidermal growth factor receptor 2 (HER2/neu). Te amplifcation of this oncogene plays an important role in the development of some aggressive types of breast cancer. COX-2 is also been reported in early tumors by stromal cells [2] and in larger tumors by dysplastic epithelium [3]. It has been proved that various infammatory cells, cytokines, chemokines, and enzymes facilitate the develop- ment of cancers from infammation [4]. A few COX-2/LOX- 2 (lipooxygenase-2) inhibitors such as sulindac, celecoxib, licofelone, and aspirin analogues have also been reported as suppressors of malignant growth of cells in vitro and in vivo [5] and Alzheimer’s disease [6]. Tis designates that there is an unfamiliar association involving cancer and infammation [7]. Nowadays no data are available concerning the potential use of anticancer agents as COX/LOX inhibitors. Recent molecular targets for the treatment of cancer are the relation between arachidonic acid (AA) and carcinogenesis because of the regulation of AA by two enzymes, cyclooxygenases (COXs) and lipoxygenases (LOXs). Prostaglandin E 2 (PGE 2 ), the main product of COX-2, is found in high concentration in tumor cells [8] and is synthesized by various human breast cancer cell lines. Te goal of this research was to achieve a novel series of agents that could have potent anticancer efcacy in association with the suppression of COX/LOX pathways. Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 386473, 9 pages http://dx.doi.org/10.1155/2014/386473